<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4213">
  <stage>Registered</stage>
  <submitdate>25/10/2013</submitdate>
  <approvaldate>25/10/2013</approvaldate>
  <nctid>NCT01973049</nctid>
  <trial_identification>
    <studytitle>UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis</studytitle>
    <scientifictitle>A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-002458-66</secondaryid>
    <secondaryid>AI443-113</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Daclatasvir
Treatment: drugs - Asunaprevir
Treatment: drugs - BMS-791325
Treatment: drugs - Ribavirin
Treatment: drugs - Placebo matching Ribavirin

Experimental: A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive) - Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks

Experimental: A2: DCV/ASV/BMS-791325 + RBV (naive) - Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
Ribavirin 200mg tablet orally twice a day for 12 weeks

Experimental: A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced) - Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks

Experimental: A4: DCV/ASV/BMS-791325 + RBV (experienced) - Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If &lt; 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if = 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening


Treatment: drugs: Daclatasvir


Treatment: drugs: Asunaprevir


Treatment: drugs: BMS-791325


Treatment: drugs: Ribavirin


Treatment: drugs: Placebo matching Ribavirin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of treated subjects in each of the naive arms with sustained virologic response (SVR12) - SVR12 is defined as Hepatitis C virus ribonucleic acid (HCV RNA) &lt; Limit of Quantification (LOQ) target detected or target not detected (LOQ TD/TND)</outcome>
      <timepoint>Post treatment 12 week</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of treated subjects in each of the experienced arms with SVR12</outcome>
      <timepoint>Post treatment 12 Week</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TD/TND</outcome>
      <timepoint>Weeks: 1, 2, 4, 6, 8, and 12; Post treatment Weeks 4 (SVR4), 8 (SVR8) and 24 (SVR24)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TND</outcome>
      <timepoint>Weeks: 1, 2, 4, 6, 8, and 12; Post treatment Weeks 4 (SVR4), 8 (SVR8), 12 (SVR12) and 24 (SVR24)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety as measured by frequency of Serious Adverse Events(SAEs)and discontinuations due to Adverse Events(AEs)</outcome>
      <timepoint>Up to end of treatment (week 12) + 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with anemia defined as Hg &lt; 10 g/dL on-treatment and Hg = 10 g/dL at baseline in each arm within each cohort</outcome>
      <timepoint>Up to end of treatment (week 12) + 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Differences in rates of selected Grade 3 - 4 laboratory test result abnormalities</outcome>
      <timepoint>Up to end of treatment (week 12) + 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome>
      <timepoint>Post treatment 12 Week</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects in each arm achieving SVR12 associated with IL28B rs12979860 single nucleotide polymorphism(SNP) status (CC genotype or non-CC genotype)</outcome>
      <timepoint>Post treatment 12 Week</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  Subjects chronically infected with HCV genotype 1

          -  Subjects with compensated cirrhosis

          -  HCV RNA = 10,000 IU/mL at screening

          -  Treatment-na√Øve subjects with no previous exposure to an interferon formulation (ie,
             IFNa, pegIFNa), Ribavirin (RBV), or HCV Direct Acting Antivirals (DAA) (protease,
             polymerase inhibitor, etc.)

          -  Treatment-experienced subjects are eligible including exposure to anti-HCV agents of a
             mechanistic class other than those contained in the Daclatasvir (DCV) / Asunaprevir
             (ASV) /BMS-791325 triple regimen is permitted. Examples of permitted agents include,
             but are not limited to nucleoside/nucleotide inhibitors of nonstructural protein 5B
             (NS5B) polymerase, inhibitors of cyclophilin, or inhibitors of microRNA.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects without cirrhosis

          -  Liver or any other organ transplant

          -  Current or known history of cancer within 5 years prior to screening

          -  Documented or suspected hepatocellular carcinoma(HCC)

          -  Evidence of decompensated liver disease including, but not limited to, radiologic
             criteria, a history or presence of ascites, bleeding varices, or hepatic
             encephalopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>202</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Darlinghurst</hospital>
    <hospital>Local Institution - Greenslopes</hospital>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Clayton</hospital>
    <hospital>Local Institution - Fitzroy</hospital>
    <hospital>Local Institution - Heidelberg</hospital>
    <hospital>Local Institution - Fremantle</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To demonstrate the effectiveness of DCV 3DAA fixed dose combination with or without Ribavirin
      in treatment naive cirrhotic subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01973049</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>